Table of Contents

Overview

Thomas J. Lynch, Jr, MD
Director, Yale Cancer Center, Physician-in-Chief
Smilow Cancer Center at Yale, New Haven

Role of Maintenance Monoclonal Antibodies

Alan B. Sandler, MD
Division Chief, Hematology/Oncology
Oregon Health and Science University, Portland

Evidence for Early Second-Line Therapy: Docetaxel and Erlotinib

Panos Fidias, MD
Clinical Director, Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center, Boston

Evidence for Early Second-Line Therapy: Pemetrexed

Nasser H. Hanna, MD, and Shadia Jalal, MD
Division of Hematology/Oncology
Indiana University School of Medicine, Indianapolis

Determining Which Approach Is Best for Your Patient

Discussion of relevant case studies presented by Dr. Lynch

References